Resverlogix Corp
Company Profile
Business description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Contact
4820 Richard Road South West
Suite 300
CalgaryABT3E 6L1
CANT: +1 403 254-9252
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
18
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
stocks
Is this overpriced ASX share too much of a gamble?
stocks
ASX players that might thrive under a Trump administration
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,539.00 | 59.10 | 0.70% |
| CAC 40 | 7,269.63 | 42.17 | -0.58% |
| DAX 40 | 19,210.81 | 52.89 | -0.27% |
| Dow JONES (US) | 43,444.99 | 305.87 | -0.70% |
| FTSE 100 | 8,063.61 | 7.58 | -0.09% |
| HKSE | 19,426.34 | 9.47 | -0.05% |
| NASDAQ | 18,680.12 | 427.53 | -2.24% |
| Nikkei 225 | 38,642.91 | 107.21 | 0.28% |
| NZX 50 Index | 12,684.88 | 8.06 | -0.06% |
| S&P 500 | 5,870.62 | 78.55 | -1.32% |
| S&P/ASX 200 | 8,285.20 | 61.20 | 0.74% |
| SSE Composite Index | 3,330.73 | 49.11 | -1.45% |